Thymosin in patient Recurrent IVF Failures

An interventional pilot Study to assess the efficacy of Thymosin Therapy in patients with genuine Recurrent Implantation Failure (RIF) with altered Immunoprofiling - NIL

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2025/02/080717

Enrollment

Registered

2025-02-17

Start date

Unknown

Completion date

Unknown

Last updated

2025-06-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: N979- Female infertility, unspecified

Interventions

Intervention1: Administration of Thymosin in RIF Pateints with dysregulation in immunoprofiling: Starting from Day 1 of HRT, administer two subcutaneous injections (1.6 mg each) every other day until

Eligibility

Inclusion criteria

Inclusion criteria: IVF patients experiencing RIF Patients who had ET of 7mm or more during previous ET. Abnormality in Immunoprofiling

Exclusion criteria

Exclusion criteria: Known immunological disease like Psoriasis, SLE, RA etc Known case of congenital/acquired thrombophilia ( APLA) Uncorrected septate uterus, myoma and adenomyoma Thin endometrium less than 7mm despite measures to improve

Design outcomes

Primary

Measure	Time frame
Ongoing Pregnancy Rate Timepoint: 12 weeks of pregnancy	—

Secondary

Measure	Time frame
Clinical pregnancy rateTimepoint: 6 weeks of gestation	—

Countries

India

Contacts

Public ContactAruna R

A4 Hospital and Fertility centre

aruna@a4fertility.com09841269578

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026